Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares (NQ:KNSA)

25.88 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

< Previous 1 2 3 4 Next >
These stocks are gapping in today's session
Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
Honeywell Posts Better-Than-Expected Q1 Earnings, Joins Crown Holdings, Noble, Crane And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Earnings Scheduled For April 29, 2025
Via Benzinga
Examining the Future: Kiniksa Pharmaceuticals's Earnings Outlook
Via Benzinga
3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now
Via The Motley Fool
Earnings Scheduled For February 25, 2025
Via Benzinga
Exploring Kiniksa Pharmaceuticals's Earnings Expectations
Via Benzinga
Earnings Outlook For Kiniksa Pharmaceuticals
Via Benzinga
Kiniksa Pharmaceuticals Stock Is Attractive From Valuation Perspective-JP Morgan Analyst
Kiniksa shifts focus to cardiovascular indications, halts abiprubart in Sjögren's, ends its AstraZeneca deal, and advances KPL-387 for recurrent pericarditis. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
NHL Hall-of-Famer, Henrik Lundqvist, Teams Up with Kiniksa Pharmaceuticals to Launch Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis
– Life DisRPted is an educational campaign aimed at promoting early diagnosis and treatment of recurrent pericarditis, a painful and debilitating chronic autoinflammatory disease – 
From Kiniksa Pharmaceuticals, Ltd.
Via GlobeNewswire
Earnings Outlook For Kiniksa Pharmaceuticals
Via Benzinga
Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
KNSA Stock Earnings: Kiniksa Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
KNSA stock results show that Kiniksa Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Danaher Posts Upbeat Earnings, Joins Spotify, MSCI, Owens & Minor And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Sector Spotlight: Orphan Drug Developers With Significant Upside
Via AB Newswire
Topics ETFs
Exposures Product Safety
Sector Spotlight: Orphan Drug Developers With Significant Upside
The biotech sector is finally beginning to recover following a two year stretch of underperformance that was largely driven by rising interest rates and other macro factors. Biotech has a track record... 
Via TheNewswire.com
Topics ETFs
Exposures Product Safety
KNSA Stock Earnings: Kiniksa Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024
KNSA stock results show that Kiniksa Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
The 3 Most Undervalued Biotech Stocks to Buy in December
Biotech is an increasing area of interest in the financial markets, line your portfolio up with these winning biotech stocks. 
Via InvestorPlace
7 Underappreciated Biotech Stocks to Pick Up on the Cheap
With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor. 
Via InvestorPlace
Topics Economy
Exposures Economy
Earnings Scheduled For April 23, 2024
Companies Reporting Before The Bell • RTX (NYSE:RTX) is expected to report quarterly earnings at $1.23 per share on revenue of $18.41 billion. 
Via Benzinga
Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Longboard Pharmaceuticals, Inc. 
Via Benzinga
Amicus Therapeutics Stock Reaches 80+ Relative Strength Benchmark
Amicus Therapeutics sees its Relative Strength Rating move into the 80-plus level. 
Via Investor's Business Daily
5 Value Stocks In The Healthcare Sector
Via Benzinga
5 Value Stocks To Watch In The Healthcare Sector
Via Benzinga
Vertex Pharmaceuticals Stock Shows Rising Relative Strength, Hits 80+
Vertex Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81. 
Via Investor's Business Daily
ACELYRIN Stock Scores Relative Strength Rating Upgrade; Hits Key Threshold
One key metric to look for in a stock is an 80-plus Relative Strength Rating. ACELYRIN stock hit that mark on Tuesday, with a jump to 81. 
Via Investor's Business Daily
Axsome Therapeutics Stock Earns Relative Strength Rating Upgrade
A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance. 
Via Investor's Business Daily
Exelixis Stock Sees Rising Relative Strength Rating
On Monday, Exelixis stock hit an key technical milestone, with its Relative Strength Rating rising to 87, an increase from 79 the day before. 
Via Investor's Business Daily
Dynavax Technologies Stock Sees Renewed Technical Strength
Dynavax Technologies shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 84. 
Via Investor's Business Daily
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.